Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms
Condition: Cigarette Smoking
Intervention: Standard Treatment; Behavioral Activation Treatment for Smoking; Transdermal Nicotine Patch
Intervention description: Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.; BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.; 8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
Intervention MeSH terms: Nicotine
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Single (Participant)
Enrollment: 184.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: No
Keywords: Smoking, Smoking Cessation

Summary:

      Depression related vulnerabilities are highly comorbid with smoking behavior and dramatically
      reduce cessation rates among both community and clinical samples. Previous research has
      examined the efficacy of cognitive-behavioral treatment for individuals with a history of
      major depressive disorder (MDD) in standard cessation treatment. A broader health impact can
      be achieved by targeting individuals with current elevated depressive symptoms to address
      their association with cessation failure. Thus the objective of the present proposal is to
      conduct a Stage II randomized controlled trial (RCT) comparing the behavioral activation
      intervention to standard treatment among a similar community sample of 200 adult smokers with
      elevated depressive symptoms. Participants will be followed over 52 weeks post-quit date and
      the larger sample size will allow for more complex analysis of cessation outcomes.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Between 18 and 65 years of age

          -  A regular smoker for at least one year

          -  Currently smoking an average of at least 10 cigarettes per day

          -  Want to quit smoking

          -  Report current elevated depressive symptoms

        Exclusion Criteria:

          -  Current Axis I disorder

          -  Psychoactive substance dependence (excluding nicotine dependence) within the past 6
             months

          -  Current use of psychotropic medication or participation in any form of psychotherapy

          -  A history of significant medical condition (e.g., cardiovascular , neurological,
             gastrointestinal), pregnancy and/or breast feeding, or other systemic illness

          -  Current use of any pharmacotherapy for smoking cessation not provided by the
             researchers during the quit attempt